Latest press releases

• 17Feb
  Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

   

• 4Feb
  Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

  

• 9Jan
  Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

   

• 9Dec
  Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

   

• 25Nov
  Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)

   

• 19Nov
  Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome